Professors Blank and Schmidt-Weber Receive Prestigious Co-Creation Funding from the Helmholtz Association

With the co-creation projects as part of the transfer campaign, the Helmholtz Association of German Research Centers ensures a seamless transition from research to application.

Helmholtz Munich and the pharmaceutical company Allergopharma are working together to take the first mRNA-based tolerogenic vaccine (a vaccine designed to make the immune system stop responding so strongly to allergic stimuli) into a clinical trial. The partnership aims to validate the efficacy of this novel therapy - initially focusing on dust mite allergy - optimize the composition of the compound and compare it with conventional therapies. The aim of the partnership is to drive the technology transfer through to pharmaceutical production.